Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma
- Univ. of Chicago, IL (United States); and others
Registration methods combine the anatomic localizing ability of CT or MRI with SPECT images of radiolabeled monocional antibodies (Mabs), allowing the accurate staging of patients prior to surgery or following treatment. Twenty-four patients (15 males and 9 females, mean age 55 yr, range 29-70 yr) were studied with this technique. Ten patients had suspected colorectal cancer recurrence and were infused with 10 mCi of {sup 131}I-CC49 prior to staging laparotomy. Fourteen patients treated in a Phase 1 radioimmunotherapy study with {sup 131}I-CC49 were also studied. All patients underwent SPECT imaging of the abdomen and pelvis 5-7 days following infusion of Mab. Phantom studies demonstrated a 3.6-mm surface fitting mean accurracy of datasets for the liver and 1.8 mm for an intrahepatic tumor. In the presurgical group, SPECT and CT/MRI registration allowed more accurate identification of uptake abnormal sites. Areas of metastatic disease > 1 cm confirmed at surgery were found in six of nine patients with liver lesions and in two patients with extrahepatic (including one patient with pelvic) disease. In patients imaged following radioimmunotherapy, all lesions > 1.5 cm seen on CT/MRI were identified, and activity distribution in tumor and normal tissue could be more accurately assessed. Routine registration of SPECT and CT/MRI images is feasible and allows more accurate anatomic assessment of sites of abnormal uptake in radiolabeled Mab studies. 41 refs., 5 figs., 2 tabs.
- OSTI ID:
- 114885
- Journal Information:
- Journal of Nuclear Medicine, Vol. 35, Issue 12; Other Information: PBD: Dec 1994
- Country of Publication:
- United States
- Language:
- English
Similar Records
Pharmacokinetics and biodistribution of intravenous Lu-177 CC49 murine monoclonal antibody (MAb) in patients with metastatic adenocarcinoma
Dosimetric potential of minimal residual disease using radiolabeled antibodies